Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer

PURPOSE: Immune checkpoint inhibitors (ICIs) are effective in only a minority of patients with esophagogastric cancer (EGC). Here, we aimed to identify predictors of durable clinical benefit to ICI in EGC. EXPERIMENTAL DESIGN: Patients with advanced EGC treated with ICIs at Memorial Sloan Kettering...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Greally, Megan, Chou, Joanne F., Chatila, Walid K., Margolis, Matthew, Capanu, Marinela, Hechtman, Jaclyn F., Tuvy, Yaelle, Kundra, Ritika, Daian, Foysal, Ladanyi, Marc, Kelsen, David P., Ilson, David H., Berger, Michael F., Tang, Laura H., Solit, David B., Diaz, Luis A., Schultz, Nikolaus, Janjigian, Yelena Y., Ku, Geoffrey Y.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6905384/
https://ncbi.nlm.nih.gov/pubmed/31337644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3603
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados